

Early-stage Development Pipeline

Phase I

3rd Generation Anti-CD20²	Dacetuzumab (Anti-CD40)
<ul style="list-style-type: none"> Chronic lymphocytic leukemia Non-Hodgkin's lymphoma 	<ul style="list-style-type: none"> Diffuse large B-cell lymphoma Multiple myeloma Non-Hodgkin's lymphoma
ABT-263	GA101
<ul style="list-style-type: none"> Chronic lymphocytic leukemia Lymphoid malignancies Small cell lung cancer 	<ul style="list-style-type: none"> Hematologic malignancies
ABT-869	IAP Antagonist
<ul style="list-style-type: none"> Non-small cell lung cancer¹ 	<ul style="list-style-type: none"> Cancer
Anti-Abeta	MEK Inhibitor
<ul style="list-style-type: none"> Alzheimer's Disease 	<ul style="list-style-type: none"> Cancer
Anti-Beta7	New Molecular Entity
<ul style="list-style-type: none"> Ulcerative colitis 	<ul style="list-style-type: none"> Autoimmune disease
Anti-CD4	New Molecular Entity
<ul style="list-style-type: none"> Rheumatoid arthritis 	<ul style="list-style-type: none"> Cancer
Anti-IFNalpha	New Molecular Entity (ADC)
<ul style="list-style-type: none"> Systemic lupus erythematosus 	<ul style="list-style-type: none"> Cancer
Anti-IL13	PI3 Kinase Inhibitor
<ul style="list-style-type: none"> Asthma 	<ul style="list-style-type: none"> Cancer
Anti-OX40L	rhApo2L/TRAIL
<ul style="list-style-type: none"> Asthma 	<ul style="list-style-type: none"> Colorectal cancer
Anti-oxLDL	Trastuzumab-DM1 + Pertuzumab
<ul style="list-style-type: none"> Secondary prevention of cardiovascular events 	<ul style="list-style-type: none"> HER2-positive metastatic breast cancer¹
Apomab	
<ul style="list-style-type: none"> Colorectal cancer 	

Phase II

ABT-869	MetMab
<ul style="list-style-type: none"> Advanced renal cell carcinoma Hepatocellular carcinoma Metastatic breast cancer Metastatic colorectal cancer¹ Metastatic non-small cell lung cancer 	<ul style="list-style-type: none"> Non-small cell lung cancer¹
Apomab	Ocrelizumab²
<ul style="list-style-type: none"> Non-Hodgkin's lymphoma Non-small cell lung cancer 	<ul style="list-style-type: none"> Relapsing remitting multiple sclerosis
Avastin	Pertuzumab
<ul style="list-style-type: none"> Extensive small cell lung cancer Non-squamous, non-small cell lung cancer with previously treated CNS metastases Relapsed multiple myeloma 	<ul style="list-style-type: none"> Non-small cell lung cancer¹ Ovarian cancer
Dacetuzumab (Anti-CD40)	Raptiva
<ul style="list-style-type: none"> Diffuse large B-cell lymphoma 	<ul style="list-style-type: none"> Renal transplantation¹
Hedgehog Inhibitor	rhApo2L/TRAIL
<ul style="list-style-type: none"> Advanced basal cell carcinoma¹ First-line metastatic colorectal cancer Ovarian cancer¹ 	<ul style="list-style-type: none"> Non-Hodgkin's lymphoma Non-small cell lung cancer
	Trastuzumab-DM1
	<ul style="list-style-type: none"> First-line HER2-positive metastatic breast cancer Second-line HER2-positive metastatic breast cancer Third-line HER2-positive metastatic breast cancer
	Xolair
	<ul style="list-style-type: none"> Chronic idiopathic urticaria¹

Legend

- Immunology
- Neuroscience
- Oncology
- Tissue Growth & Repair

As of October 14, 2008

1) Preparing for phase.

2) Our collaborator Biogen Idec disagrees with certain of our development decisions under our 2003 collaboration agreement. We continue to pursue a resolution of our differences with Biogen Idec. The disputed issues were submitted to arbitration in San Francisco, California and a hearing was held in September 2008 with a concluding hearing to take place in December 2008. We expect that we will receive a ruling by approximately June 2009. The arbitration proceedings with Biogen Idec are confidential and we will not provide details on the program disagreements with Biogen Idec nor the hearing discussions.

ADC = Antibody Drug Conjugate; CNS = Central Nervous System.